Skip to main content
Premium Trial:

Request an Annual Quote

Roberto Guerciolini

Dicerna, an RNAi drug startup based in Boston (see related story, this issue), has appointed Roberto Guerciolini as senior vice president of pharmaceutical development.
Guerciolini, who is also a co-founder of Dicerna, was previously the senior vice president of development and chief medical officer of Sirna Therapeutics.
Before that, he served as senior director of clinical pharmacology and experimental medicine at Millennium Pharmaceuticals. He has also held various positions at Hoffman-La Roche and Schering-Plough.

He holds an MD in internal medicine from the University of Perugia Medical School and an MBA from the Hass School of Business at the University of California, Berkeley.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.